Implement detection of KRAS and NRAS variants interfering with metastatic colorectal cancer (mCRC) therapies.
Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. KRAS and NRAS StripAssays® identify the most relevant genetic variants of KRAS and NRAS genes interfering with treatment/therapy success.
KRAS & NRAS
- Inhibiting EGFR with anti-EGFR mAbs prevents activation of the relevant signal transduction pathway. However, certain mutations in RAS genes result in permanent activation of parts of this pathway, rendering anti-EGFR therapies ineffective.
- Prior to treatment with anti-EGFR mAbs, mCRC patients should be tested for RAS variants, as positive patients are unlikely to benefit from this kind of therapy.
- KRAS and NRAS StripAssays® assist clinicians in the stratification of patients considered for anti-EGFR mAb therapies (i.e. cetuximab or panitumumab).